Skip to main content
Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: Effects of 6-month eicosapentaenoic acid treatment on postprandial hyperglycemia, hyperlipidemia, insulin secretion ability, and concomitant endothelial dysfunction among newly-diagnosed impaired glucose metabolism patients with coronary artery disease. An open label, single blinded, prospective randomized controlled trial

Fig. 2

Categorical allocation according to glucose tolerance at baseline and after 6 months. Numbers on the lines represent the number of patients transferred between glucose categories. Deteriorated patients were significantly larger in the non-EPA group, while improved patients were significantly larger in the EPA group (deteriorated glucose tolerance; seven patents in the non-EPA group vs two patients in the EPA group, improved glucose tolerance; 11 patients in the non-EPA group vs 25 patients in the EPA group, p = 0.01). Comparison was performed using χ2 test

Back to article page